At a glance
ClinicalIndex Comparison RecordN/ACompleted· 55 enrolled
Drug / intervention
botulinum toxin Type Abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
In Brief
An observational study evaluating botulinum toxin Type A for Urinary Incontinence. Completed, enrolled 55 participants across 6 sites.
Detailed Summary
This study will evaluate the impact of BOTOX® treatment on anticholinergic drug use in patients with urinary incontinence from Neurogenic Detrusor Overactivity (NDO) due to spinal injury or Multiple Sclerosis (MS) who are prescribed BOTOX® as standard of care in clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Incontinence
CountriesBelgium
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
First PostedFeb 2014
Primary CompletionSep 2015
TodayJul 2026
First PostedFeb 27, 2014
Enrollment StartJan 28, 2014
Primary CompletionSep 30, 2015
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 12.3 years ago
Interventions
botulinum toxin Type Abiological
botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.